Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Ribozyme pharmacokinetic screening for predicting pharmacodynamic dosing regimens.

T J Parry1, K S Bouhana, K S Blanchard

  • 1Human Genome Sciences, Inc, Rockville, MD 20850, USA.

Current Issues in Molecular Biology
|July 27, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Quantitative low-dose assessment of seafood toxin, domoic acid, in the rat brain: application of physiologically-based pharmacokinetic (PBPK) modeling.

Environmental toxicology and pharmacology·2011
Same author

Urotensin-II induces ear flushing in rats.

British journal of pharmacology·2007
Same author

Characterization of nuclease-resistant ribozymes directed against hepatitis B virus RNA.

Journal of viral hepatitis·2002
Same author

Enhanced antiviral effect in cell culture of type 1 interferon and ribozymes targeting HCV RNA.

Journal of viral hepatitis·2001
Same author

Pharmacokinetics and tolerability of an antiangiogenic ribozyme (ANGIOZYME) in healthy volunteers.

Journal of clinical pharmacology·2001
Same author

Pharmacokinetics and immunological effects of exogenously administered recombinant human B lymphocyte stimulator (BLyS) in mice.

The Journal of pharmacology and experimental therapeutics·2001

Pharmacokinetic analysis optimizes dosing for synthetic ribozymes like ANGIOZYME, which targets vascular endothelial growth factor receptor (Flt-1) mRNA. This approach is crucial for developing systemic therapies against metastatic cancer.

Area of Science:

  • Molecular Biology
  • Pharmacology
  • Oncology

Background:

  • Synthetic ribozymes are being chemically stabilized for systemic disease applications.
  • ANGIOZYME, a nuclease-stabilized hammerhead ribozyme, targets Flt-1 mRNA, a receptor implicated in tumor growth and metastasis.
  • Flt-1 receptor stimulation may drive tumor neovascularization, growth, and metastasis.

Purpose of the Study:

  • To explore the systemic use of ANGIOZYME to downregulate Flt-1 in a murine model of metastatic cancer.
  • To apply pharmacokinetic analysis for selecting an optimal dosing regimen for pharmacodynamic screening.
  • To demonstrate the necessity of pharmacokinetic analysis for optimizing systemic synthetic ribozyme studies.

Main Methods:

  • Development of a nuclease-stabilized synthetic hammerhead ribozyme (ANGIOZYME).

Related Experiment Videos

  • Targeting of vascular endothelial growth factor receptor (Flt-1) mRNA.
  • Application of pharmacokinetic analysis to determine dosing regimens.
  • Pharmacodynamic screening in a syngeneic murine model of metastatic cancer.

    • Main Results:

    • Pharmacokinetic analysis was applied to select a dosing regimen for ANGIOZYME.
    • The study explored the systemic administration of ANGIOZYME in a cancer model.
    • The results underscore the importance of pharmacokinetic analysis in this context.

    Conclusions:

    • Appropriate pharmacokinetic analysis is essential for optimizing systemic pharmacodynamic studies.
    • This approach is necessary for the effective systemic use of synthetic ribozymes.
    • Optimized dosing regimens are critical for the therapeutic potential of synthetic ribozymes in cancer treatment.